SEARCH

SEARCH BY CITATION

References

  • 1
    Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J 2004;24: 758764.
  • 2
    Linneberg A, Nielsen NH, Madsen F, Frolund L, Dirksen A, Jorgensen T. Increasing prevalence of specific IgE to aeroallergens in an adult population: two cross-sectional surveys 8 years apart. The Copenhagen Allergy Study. J Allergy Clin Immunol 2000;106: 247252.
  • 3
    Bousquet J, Van Cauwenberge P, Khaltaev N, Aria Workshop Group, World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108(Suppl. 5):147334.
  • 4
    Moller C, Dreborg S, Ferdousi HA, Halken S, Host A, Jacobsen L et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002;109: 251256.
  • 5
    Linneberg A, Nielsen NH, Madsen F, Frolund L, Dirksen A, Jorgensen T. Secular trends of allergic asthma in Danish adults. The Copenhagen Allergy Study. Respir Med 2001;95: 258264.
  • 6
    Burney P, Malmberg E, Chinn S, Jarvis D, Luczynska C, Lai E. The distribution of total and specific serum IgE in the European Community Respiratory Health Survey. J Allergy Clin Immunol 1997;99: 314322.
  • 7
    White P, Smith H, Baker N, Davis W, Frew A. Symptom control in patients with hay fever in UK general practice: how well are we doing and is there a need for allergen immunotherapy? Clin Exp Allergy 1998;28: 266270.
  • 8
    Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ 1991;302: 265269.
  • 9
    Walker SM, Varney VA, Gaga M, Jacobson MR, Durham SR. Grass pollen immunotherapy: efficacy and safety during a 4-year follow-up study. Allergy 1995;50: 405413.
  • 10
    Dolz I, Martínez-Cócera C, Bartolomé JM, Cimarra M. A double-blind, placebo-controlled study of immunotherapy with grass-pollen extract Alutard SQ during a 3-year period with initial rush immunotherapy. Allergy 1996;51: 489500.
  • 11
    Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999;341: 468475.
  • 12
    Mosbech H, Osterballe O. Does the effect of immunotherapy last after termination of treatment? Follow-up study in patients with grass pollen rhinitis. Allergy 1988;43: 523529.
  • 13
    Bousquet J, Lockey RF, Malling HJ. WHO Position Paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 1998;53: 142.
  • 14
    Canonica GW, Passalacqua G. Noninjection routes for immunotherapy. J Allergy Clin Immunol 2003;111: 437448.
  • 15
    Khinchi MS, Poulsen LK, Carat F, Andre C, Hansen AB, Malling HJ. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy 2004;59: 4553.
  • 16
    Smith H, White P, Annila I, Poole J, Andre C, Frew A. Randomized controlled trial of high-dose sublingual immunotherapy to treat seasonal allergic rhinitis. J Allergy Clin Immunol 2004;114: 831837.
  • 17
    Passalacqua G, Canonica GW. Sublingual or injection immunotherapy: the final answer? Allergy 2004;59: 3738.
  • 18
    Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. Republic of South Africa: Declaration of Helsinki, 1996 (October).
  • 19
    Global Initiative for Asthma. Global strategy for asthma management and prevention. Bethesda, Maryland, USA: National Heart, Lung and Blood Institute, National Institute of Health, 2002 (Report No. 02-3659).
  • 20
    Wilson DR, Torres LM, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005;60: 412.
  • 21
    Juniper EF, Stahl E, Doty RL, Simons FE, Allen DB, Howarth PH. Clinical outcomes and adverse effect monitoring in allergic rhinitis. J Allergy Clin Immunol 2005;115(3 Pt 2):S390S413.
  • 22
    Jacobsen L. Preventive aspects of immunotherapy: prevention for children at risk of developing asthma. Ann Allergy Asthma Immunol 2001;87(1 Suppl. 1):4346.
  • 23
    Novembre E, Galli E, Landi F, Caffarelli C, Pifferi M, De ME et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 2004;114: 851857.